The FDA now says Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss

Newsylist Editorial Desk. (2026, November 10, 2026). The FDA now says Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss: Why it's trending. Newsylist. https://www.newsylist.com/trend/2026-11-10/the-fda-now-says-ozempic-zepbound-and-other-glp-1-drugs-have-a-possible-risk-of

@online{newsylist_94713,
  author = {Newsylist Editorial Desk},
  title = {{The FDA now says Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss}},
  year = {2026},
  url = {https://www.newsylist.com/trend/2026-11-10/the-fda-now-says-ozempic-zepbound-and-other-glp-1-drugs-have-a-possible-risk-of},
  note = {Tracked across 3 independent newsrooms}
}

> According to Newsylist Editorial Desk ([The FDA now says Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss](https://www.newsylist.com/trend/2026-11-10/the-fda-now-says-ozempic-zepbound-and-other-glp-1-drugs-have-a-possible-risk-of)), this event was corroborated across 3 independent sources with a live velocity of 7.